Phio Pharmaceuticals
PHIO
2 hedge funds and large institutions have $139K invested in Phio Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 2 closing their positions.
5% more capital invested
Capital invested by funds: $132K → $139K (+$7K)
0% less ownership
Funds ownership: 0% → 0% (-0%)
33% less funds holding
Funds holding: 3 → 2 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$34.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$34K |
| 2 |
Millennium Management
New York
|
-$16K |
| 3 |
Goldman Sachs
New York
|
-$9K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TSS
1
Two Sigma Securities
New York
| $23K | – | – | – |
|
|
2
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $18K | +$34.2K | +1 | New |
|
3
Citadel Advisors
Miami,
Florida
| $16K | – | – | – |
|
4
Geode Capital Management
Boston,
Massachusetts
| $14K | – | – | – |
|
|
VF
5
Virtu Financial
New York
| $14K | – | – | – |
|
|
IP
6
Intellectus Partners
San Francisco,
California
| $11K | – | – | – |
|
|
RJFSA
7
Raymond James Financial Services Advisors
St. Petersburg,
Florida
| $11K | – | – | – |
|
8
Vanguard Group
Malvern,
Pennsylvania
| $10K | – | – | – |
|
9
UBS Group
Zurich,
Switzerland
| $9K | – | – | – |
|
10
Northern Trust
Chicago,
Illinois
| $7K | – | – | – |
|
11
BlackRock
New York
| $6K | – | – | – |
|
|
BDWM
12
Brewin Dolphin Wealth Management
Conskleagh, Dublin,
Ireland
| $6 | – | – | – |
|
|
13
Millennium Management
New York
| – | -$16K | -1 | Closed |
|
|
PAM
14
Panagora Asset Management
Boston,
Massachusetts
| – | -$34K | -1 | Closed |
|
|
15
Goldman Sachs
New York
| – | -$9K | – | – |
|
PHIO Hedge Fund Activity: Q4 2017 in Review
2 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Phio Pharmaceuticals (PHIO) for Q4 2017, worth a combined $139K — up 5.3% from $132K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of PHIO and 1 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $34.2K. The largest seller was Panagora Asset Management, exiting entirely with an estimated $34K sold.
- 2 institutional investors held Phio Pharmaceuticals (PHIO) as of Q4 2017, down from 3 in Q3 2017.
- Funds reported $139K of Phio Pharmaceuticals stock for Q4 2017, up 5.3% quarter-over-quarter.
- 1 fund opened new Phio Pharmaceuticals positions in Q4 2017 and 2 closed out, a net change of -1 holder.
- The largest Phio Pharmaceuticals buyer in Q4 2017 was Susquehanna International Group, an estimated $34.2K added.
- The largest Phio Pharmaceuticals seller in Q4 2017 was Panagora Asset Management, an estimated $34K sold.
Based on aggregated 13F filings for Q4 2017.